Tocagen Inc (NASDAQ:TOCA) was the recipient of a significant decline in short interest during the month of October. As of October 13th, there was short interest totalling 490,006 shares, a decline of 37.5% from the September 29th total of 783,892 shares. Based on an average daily volume of 125,307 shares, the days-to-cover ratio is presently 3.9 days. Currently, 2.9% of the company’s stock are short sold.
Several hedge funds and other institutional investors have recently made changes to their positions in TOCA. TD Asset Management Inc. bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $158,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $165,000. Alps Advisors Inc. bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $215,000. Bank of New York Mellon Corp bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $281,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $837,000. 37.87% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently weighed in on TOCA. Zacks Investment Research upgraded Tocagen from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $24.00 price target on shares of Tocagen in a research report on Tuesday, July 25th.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.04). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million.
ILLEGAL ACTIVITY WARNING: “Short Interest in Tocagen Inc (TOCA) Decreases By 37.5%” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/11/02/short-interest-in-tocagen-inc-toca-decreases-by-37-5.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
What are top analysts saying about Tocagen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tocagen Inc and related companies.